Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 9/20 | 0.54 |
| ▸ | IL1B | P01584 | 1/20 | 0.50 |
| ▸ | ELANE | P08246 | 2/20 | 0.47 |
| ▸ | CASP3 | P42574 | 8/20 | 0.46 |
| ▸ | CASP6 | P55212 | 6/20 | 0.46 |
| ▸ | CASP8 | Q14790 | 6/20 | 0.46 |
| ▸ | CTRC | Q99895 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12914456 | 0.91 | CASP1 (0.62) | CASP1IL1BCASP3CASP6CASP8 | |
| SCHEMBL645752 | 0.91 | CASP1 (0.62) | CASP1IL1BCASP3CASP6CASP8 | |
| SCHEMBL950212 | 0.80 | CASP1 (0.61) | CASP1IL1BELANE | |
| SCHEMBL12450470 | 0.80 | CASP1 (0.61) | CASP1IL1BELANE | |
| SCHEMBL4454200 | 0.79 | CASP1 (0.77) | CASP1IL1BELANECTRC | |
| SCHEMBL950559 | 0.78 | ELANE (0.53) | CASP1IL1BELANECTRC | |
| SCHEMBL647546 | 0.78 | CASP3 (0.57) | CASP1ELANECASP3CASP6CASP8 | |
| SCHEMBL951210 | 0.75 | CASP1 (0.73) | CASP1IL1BELANECTRC | |
| SCHEMBL12450461 | 0.75 | CASP1 (0.67) | CASP1IL1BELANECTRC | |
| SCHEMBL12450458 | 0.74 | CASP1 (0.71) | CASP1IL1BELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120238749-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-09-20 | — | — | US | disclosed |
| US-20120238749-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238749-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | IL1B, IL1A, IL1R1 | CASP1 5/4885IL1B 1/4885ELANE 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.